Leica Biosystems Expanded Digital Pathology Portfolio with Multiple FDA Clearances
On 11 August 2026, Leica Biosystems announced that it had received multiple U.S. FDA 510(k) clearances for its connected clinical digital pathology portfolio. The regulatory clearances strengthened the company's digital pathology offerings and supported faster, more consistent cancer diagnosis by improving laboratory workflow efficiency.
The expanded portfolio included the FDA-cleared Aperio iQC DX software, the new Aperio GT 180 DX digital pathology scanner, and enhanced clinical capabilities for the Aperio GT 450 DX scanner. These additions provided pathology laborat...